Hepatitis C primary prevention

Jump to navigation Jump to search

Hepatitis Main Page

Hepatitis C

Home

Patient Info

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Epidemiology & Demographics

Risk Factors

Screening

Differentiating Hepatitis C from other Diseases

Natural History, Complications & Prognosis

Diagnosis

History & Symptoms

Physical Examination

Lab Tests

Electrocardiogram

Chest X Ray

CT

MRI

Ultrasound

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Future or Investigational Therapies

Hepatitis C primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hepatitis C primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hepatitis C primary prevention

CDC on Hepatitis C primary prevention

Hepatitis C primary prevention in the news

Blogs on Hepatitis C primary prevention

Directions to Hospitals Treating Hepatitis C

Risk calculators and risk factors for Hepatitis C primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-In-Chief: Javaria Anwer M.D.[2]

Overview

In the absence of available vaccine, primary prevention of HCV depends mostly on avoiding exposure to the virus.

Primary Prevention

Unlike hepatitis A and hepatitis B, there are currently no readily available vaccines for hepatitis C. Primary prevention of HCV relies mostly on measures that decrease exposure to the virus. Recommendations are based on the routes of transmission, and populations at risk. Based on CDC/ AASLD/IDSA recommendations, one-time, routine, opt-out HCV testing is recommended for all individuals aged 18 years or older. For individuals younger than 18 years, HCV testing should be performed in the setting of exposures, and conditions and behaviors where increased risk of HCV is anticipated.[1]

Recommendations for healthcare workers[2]

  • Proper hand hygiene and use of gloves when indicated
  • Safe handling and disposal of sharps and contaminated waste
  • Train healthcare personnel
  • Test donated blood
  • Improve access to safe blood
  • Health care, emergency medical, and public safety workers after sticks with needles or sharps or mucosal exposure to HCV-infected blood should be screened.

Recommendations for IV drug users[2]

  • IV drug users should be offered the rapid hepatitis B vaccine regimen
  • Implement sterile needle and syringe programmes
  • Offer peer interventions to IV drug users
  • Offer opioid substitution therapy to treat opioid dependence to decrease risky behavior

Recommendations for sexual transmission of HCV[2]

  • Promote correct and consistent condom use
  • Routine screening of sex workers in high-prevalence settings
  • Eliminate discrimination and gender violence.
  • Annual HCV testing for PWID and HIV-seropositive men who have unprotected sexual intercourse with men. Periodic testing should be offered to other individuals with ongoing risk factors for exposure to HCV.[1]

Recommendations for pregnant females and children born to the infected[1] One-time screening of pregnant females is recommended unless risk factors require additional testing.

Recommended screening for individuals with risk exposures[1]

Vaccinations[3]

References

  1. 1.0 1.1 1.2 1.3 Kaplan, David E. (2020). "Hepatitis C Virus". Annals of Internal Medicine. 173 (5): ITC33–ITC48. doi:10.7326/AITC202009010. ISSN 0003-4819.
  2. 2.0 2.1 2.2 World Health Organization (WHO) 2014. Guidelines for the screening, care and treatment of persons with hepatitis C infection.http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/. Accessed online on July 24,2014.
  3. Cacoub P, Desbois AC, Comarmond C, Saadoun D (November 2018). "Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis". Gut. 67 (11): 2025–2034. doi:10.1136/gutjnl-2018-316234. PMID 29703790.

Template:WH Template:WS

Cookies help us deliver our services. By using our services, you agree to our use of cookies.

Navigation menu